Not saying rNAPc2 is the ticket, it's probably not. I think it may have been partnered with sgp before dndn got the cvas cash.
But there's a ton of pharma castoffs that have created an absolute massive amount of market cap. Top of my head, celexa, all of myogen, all of idenix, ranexa, cbst, all of vicuron, vx-950 was with lly, cialis was with gsk and on and on, all were big pharma throwaways. Probably an equal number on the other side, such as indiplon, actimmune and others that didn't work out well. I'd guess the success % is no better or worse than normal pharma percentages. It's still a crap shoot :) |
